Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register


Register for Free
Already have an account? Click here to log in


Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.



  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.


New and Noteworthy
Education Initiative in Hematology

  • Lymphoma — First-Line Treatment of Patients with Aggressive B-Cell Non-Hodgkin Lymphoma – Video Case Vignette
    • In this case-based video vignette, Julie Vose, MD, MBA, models how to make treatment decisions in patients with aggressive B-cell non-Hodgkin lymphoma based on disease characteristics and patient needs, preferences, and comorbidities. Do you know which patients may do better with an extended R-CHOP regimen ... more >>
    J. Vose, MD
  • Lymphoma — First-Line and Follow-Up Therapy for a Patient with Anaplastic Large Cell Lymphoma – Video Case Vignette
    • Without a standard of care for managing aggressive forms of peripheral T-cell lymphoma, such as anaplastic large cell lymphoma, clinicians and patients must choose from among multiple therapeutic options, including clinical trials. In this case-based video vignette, Lauren Pinter-Brown, MD, follows a patient ... more >>
    L. Pinter-Brown, MD
  • Lymphoma — Patients with Cutaneous T-Cell Lymphoma – Video Case Vignette
    • Mycosis fungoides and Sézary syndrome are the most common forms of cutaneous T-cell lymphoma. Join Steven M. Horwitz, MD, as he discusses two cases of progressive disease and demonstrates a stage-based treatment approach.
    S. Horwitz, MD
  • Multiple Myeloma — Case Studies in Multiple Myeloma – Living Medical eTextbook Chapter
    • Case Studies in Multiple Myeloma reviews four different real-life case scenarios in the treatment of multiple myeloma: induction therapy in a newly diagnosed patient; maintenance therapy following induction therapy and transplantation; and two cases using salvage treatment regimens—one for a patient with high ... more >>
    S. Lonial, MD
  • Multiple Myeloma — Multiple Myeloma – Living Medical eTextbook
    • This point-of-care eHandbook delivers a thorough yet concise review of multiple myeloma (MM), its diagnosis and prognosis, and the latest evidence-based data on treatment strategies with insights from top clinical specialists on the novel and emerging therapies that are revolutionizing the management of MM. ... more >>
    S. Lonial, MD
  • Multiple Myeloma — Current and Future Perspectives on the Epidemiology of Multiple Myeloma – Living Medical eTextbook Chapter
    • Multiple myeloma (MM) affects more than 70,000 persons in the United States, and is the second most common hematologic cancer. Research is moving forward in the area of inherited predisposition to MM, and recent trends demonstrate increased survival over time, although there is room for improvement. Learn ... more >>
    S. Lonial, MD
  • Multiple Myeloma — Etiology and Cellular and Molecular Pathogenesis of Multiple Myeloma – Living Medical eTextbook Chapter
    • This chapter focuses specifically on the pathogenesis of multiple myeloma (MM), providing an overview of the cell biology of myeloma cell interactions in the bone marrow as they relate to prognosis and therapeutic strategies. Up-to-date information on MM oncogenomics, as they relate to patient prognosis and ... more >>
    S. Lonial, MD
  • Multiple Myeloma — Diagnosis, Disease Classification, and Prognosis in Multiple Myeloma – Living Medical eTextbook Chapter
    • This chapter focuses specifically on the diagnosis and disease stratification of multiple myeloma, providing a review of the diverse elements that are required to accurately diagnose and stage patients with myeloma. Up-to-date information on the molecular genetic stratification of patients with multiple ... more >>
    S. Lonial, MD
  • Multiple Myeloma — Evolving Management Strategies: Current and Emerging Treatments for Induction and Maintenance Therapy in Multiple Myeloma – Living Medical eTextbook Chapter
    • The management of multiple myeloma has changed dramatically with the availability of novel antimyeloma agents. Treatment regimens incorporating these agents for induction therapy have demonstrated great improvements in complete response, and evidence is accumulating for their use in maintenance therapy. ... more >>
    S. Lonial, MD
  • Multiple Myeloma — Evolving Management Strategies: Current and Emerging Treatments for Relapsed/Refractory Multiple Myeloma – Living Medical eTextbook Chapter
    • Novel treatments for multiple myeloma (MM) have greatly improved response to first-line therapy. However, MM remains incurable, and even patients who have a good response to initial therapy ultimately relapse. Over time, patients often become refractory to multiple treatments. Fortunately, there are numerous ... more >>
    S. Lonial, MD
  • Lymphoma Video Vignettes
    • Stephanie A. Gregory, MD chairs this free point-of-care clinical companion that focuses on the treatment and management of lymphomas—including B-cell lymphoma, aggressive B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma and more —through a collection of six patient video case vignettes.
    S. Gregory, MD
  • Case-Based Video Vignettes: Chronic Myelogenous Leukemia
    • Moshe Talpaz, MD chairs this free point-of-care clinical companion that focuses on the treatment and management of chronic myelogenous leukemia (CML)—including guidance on second-generation tyrosine kinase inhibitors (TKIs) that were recently approved for first-line therapy—through a collection of six patient ... more >>
    M. Talpaz, MD
  • Multiple Myeloma
    • This point-of-care eHandbook delivers a thorough yet concise review of multiple myeloma (MM), its diagnosis and prognosis, and the latest evidence-based data on treatment strategies with insights from top clinical specialists on the novel and emerging therapies that are revolutionizing the management of MM. ... more >>
    S. Lonial, MD
  • Insights into Managing Leukemia & MDS Edition
    • What are the different types of leukemia and how can they be differentiated? What patients are at risk for the development of leukemia, and what methods are currently used to screen and diagnose these patients? What treatments are currently available for the different types of leukemia, and what agents are ... more >>
    J. Radich, MD
  • Insights into Managing Non-Hodgkin B-Cell Lymphoma
    • The physician treating a patient with a B-cell non-Hodgkin lymphoma (NHL) must develop a treatment plan appropriate for the disease subtype, presentation, and the patient's therapy preferences. This Living Medical eTextbook describes the diagnosis and prognostic classification of B-cell NHLs, current ... more >>
    S. Gregory, MD
  • Leukemia — Practice Tools to Manage Patients with Chronic Phase CML – Practice Tool
    • Download this free tips card on chronic phase CML management, which contains definitions and milestones of response to first-line therapy, and outlines next steps for patients with incomplete/no response to initial therapy, with and without resistance mutations.
  • Lymphoma — First-Line Treatment of Patients with Aggressive B-Cell Non-Hodgkin Lymphoma – Video Case Vignette
    • In this case-based video vignette, Julie Vose, MD, MBA, models how to make treatment decisions in patients with aggressive B-cell non-Hodgkin lymphoma based on disease characteristics and patient needs, preferences, and comorbidities. Do you know which patients may do better with an extended R-CHOP regimen ... more >>
    J. Vose, MD
  • Lymphoma — First-Line and Follow-Up Therapy for a Patient with Anaplastic Large Cell Lymphoma – Video Case Vignette
    • Without a standard of care for managing aggressive forms of peripheral T-cell lymphoma, such as anaplastic large cell lymphoma, clinicians and patients must choose from among multiple therapeutic options, including clinical trials. In this case-based video vignette, Lauren Pinter-Brown, MD, follows a patient ... more >>
    L. Pinter-Brown, MD
  • Lymphoma — Patients with Cutaneous T-Cell Lymphoma – Video Case Vignette
    • Mycosis fungoides and Sézary syndrome are the most common forms of cutaneous T-cell lymphoma. Join Steven M. Horwitz, MD, as he discusses two cases of progressive disease and demonstrates a stage-based treatment approach.
    S. Horwitz, MD
  • Lymphoma — First-Line Treatment of Patients with Indolent B-Cell Non-Hodgkin Lymphoma – Video Case Vignette
    • In this case-based video podcast, Stephanie A. Gregory, MD, addresses the important decision of whether to “watch and wait” or to treat patients with follicular non-Hodgkin lymphoma. By following two patients—one asymptomatic and with low tumor burden, and the other symptomatic and with high tumor burden—she ... more >>
    S. Gregory, MD
  • Leukemia — Treatment Adherence in CML – Video Case Vignette
    • One challenge of developing a treatment strategy for patients with chronic myelogenous leukemia (CML) is tailoring treatment with consideration to efficacy as well as tolerability. Poor adherence has a dramatic effect on long-term outcomes to tyrosine kinase inhibitor (TKI) therapy in patients with ... more >>
    D. Bixby, MD, PhD
  • Leukemia — Prevention and Management of Treatment-Related Side Effects in CML – Video Case Vignette
    • One challenge of developing a treatment strategy for patients with chronic myelogenous leukemia (CML) is tailoring treatment with consideration to efficacy as well as tolerability. Join Michael J. Mauro, MD, as he follows the course of two patients with chronic phase CML, each with unique medical histories. ... more >>
    M. Mauro, MD
  • Leukemia — Genetic Mutation Analysis and Implications for Patient Management in CML – Video Case Vignette
    • In this video podcast, Jerald P. Radich, MD, follows two patients who fail to meet treatment milestones while on tyrosine kinase inhibitor (TKI) therapy. He demonstrates how mutation analysis can help identify the cause of treatment failure as well guide subsequent treatment decisions, particularly the ... more >>
    J. Radich, MD
  • Leukemia — Response Criteria in Chronic Myeloid Leukemia: Importance and Appropriate Use – Video Case Vignette
    • How do you use treatment milestones to identify relapse in CML patients? When should failure to achieve a treatment milestone trigger a change in therapy? Join Michael Deininger, MD, PhD, as he follows two cases from diagnosis through important treatment milestones.
    M. Deininger, MD, PhD
  • Leukemia — Imatinib Resistant CML: The Role of Second-Generation TKIs – Video Case Vignette
    • Join Moshe Talpaz, MD, as he presents two cases that demonstrate the role of second-generation tyrosine kinase inhibitors, nilotinib and dasatinib, in patients who have developed intolerable side effects with or resistance to imatinib.
    M. Talpaz, MD
  • Leukemia — A New Era in the Management of CML: The Expanded Role of Second-Generation TKIs – Video Case Vignette
    • Second-generation tyrosine kinase inhibitors (TKI) are good options as initial therapy for newly diagnosed patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML), as well as second-line therapy when tolerability issues develop in response to prior therapy with imatinib. Join Michael ... more >>
    M. Mauro, MD